市場調查報告書
商品編碼
1563124
止血和組織封閉劑的全球市場:依產品、材料、應用、最終用戶和地區的預測(~2032年)Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product, By Material, By Application, By End-User, and Region Forecast till 2032 |
止血和組織封閉劑市場規模預計將從2023年的83.9億美元,2024年的90.2億美元,到2032年將成長到181.9億美元,預測期內年複合成長率為 8.04%。道路交通事故和慢性血液疾病發病率上升、全球對微創手術的需求以及人口老化等因素推動市場擴張。
慢性血液疾病盛行率的增加是推動市場成長的因素。患有某些血液疾病(例如血友病和馮維勒布蘭德病)的人凝血因子較低,更容易出血。對患有這些疾病的人進行手術和藥物干預時可能需要使用止血劑,以促進血液凝固和控制出血。國際血栓與止血學會2022年最新版估計,全球每年約有1,000萬例靜脈血栓栓塞病例。據該組織表示,歐洲每年有 544,000 人死於深部靜脈血栓(DVT)。
區域洞察
2023年北美藥品市場佔最大市佔率。這是由於人口老化、慢性病的增加以及醫療技術的進步。該市場致力於改善患者治療效果和減少術後併發症,已發展成為研發中心,並不斷推出具有卓越療效的新療法。
由於有利的醫療政策和包括諮詢在內的聯合治療,歐洲市場預計將佔據第二大市場佔有率。
估計2024年至2032年亞太市場將以最快的速度發展。這是由於經濟快速擴張、中產階級不斷壯大以及都市化進程不斷加速。該地區的人口成長推動對醫療保健、技術和消費品的需求。對基礎設施、教育和技術的大力投資推動產業發展和創新。
本報告調查了全球止血劑和組織封閉劑市場,提供市場的定義和概述,市場成長的各種影響因素分析,市場規模推移和預測,各種區分、地區的細分,競爭環境,主要企業概況等彙整資料。
Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product (Topical Hemostat, Adhesive & Tissue Sealant), By Material (Chitosan-based Products, Mineral based Products), By Application (Trauma, General Surgery, Minimally Invasive Surgery, Gynecology Others), By End-User (Hospitals, Ambulatory Surgical Centers, Research Institutes), and Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032
In 2023, the market for hemostasis and tissue sealing agents was estimated to be worth USD 8.39 billion. The Hemostasis and Tissue Sealing Agents Market is expected to increase from USD 9.02 billion in 2024 to USD 18.19 billion by 2032, with a compound annual growth rate (CAGR) of 8.04% over the forecast period (2024-2032). Rising rates of traffic accidents and chronic blood problems, a global demand for minimally invasive procedures, and an aging population are driving market expansion.
The increasing prevalence of chronic blood diseases is another element driving market growth. Individuals with certain blood disorders, such as hemophilia or von Willebrand disease, are more likely to bleed because their clotting factors are compromised. Hemostasis drugs, which enhance blood clotting and limit bleeding, may be required in surgical procedures or medicinal interventions for people with these conditions. For example, the International Society on Thrombosis and Hemostasis' 2022 update estimates that approximately 10 million cases of venous thromboembolism occur globally each year. According to the same source, 544,000 persons in Europe die each year from Deep Vein Thrombosis (DVT).
Market Segment insights
Hemostasis and Tissue Sealing Agents Product-based market segmentation includes Topical Hemostat and adhesive & tissue sealant.
The market is segmented by material, which comprises chitosan-based products and mineral-based products.
The market is segmented by end user, which includes hospitals, ambulatory surgical centers, and research institutes.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Hemostasis and Tissue Sealing Agents market had the biggest market share in 2023. Because of the aging population, the rising prevalence of chronic diseases, and the ongoing advancement of medical technology. With a focus on improving patient outcomes and lowering postoperative complications, the market has evolved into a hub for research and development, resulting in the introduction of novel treatments with superior efficacy.
The European Hemostasis and Tissue Sealing Agents market is estimated to account for the second-largest market share due to favorable health policies and a tendency toward combining Hemostasis and Tissue Sealing Agents, including counseling. Furthermore, the German Hemostasis and Tissue Sealing Agents market was found to have the greatest market share, while the French Hemostasis and Tissue Sealing Agents market is predicted to be the fastest-growing market in the European area.
The Asia-Pacific Hemostasis and Tissue Sealing Agents market is estimated to develop at the quickest rate between 2024 and 2032. This is the result of rapid economic expansion, a growing middle class, and greater urbanization. The region's growing population fuels demand for healthcare, technology, and consumer products. Robust investments in infrastructure, education, and technology drive industrial development and innovation.
The Middle East, Africa, and Latin America are all part of the Rest of the World. The primary drivers driving the rise of Hemostasis and Tissue Sealing Agents in the Middle East and Africa. MEA region has experienced. Increased healthcare spending and infrastructure expansion are boosting demand for innovative medical equipment.
Key Market Players
Johnson & Johnson (US), B Braun Medical Inc (Germany), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), and Pfizer Inc (US) are the market's leading players.